Response to induction therapy
| . | Number (%) . | P value . | |||||
|---|---|---|---|---|---|---|---|
| Preimatinib cohort (N = 266) . | Imatinib cohort . | ||||||
| Any imatinib (N = 175) . | Late imatinib (N = 86) . | Early imatinib (N = 89) . | Preimatinib vs any imatinib . | Late vs early imatinib . | Pre vs late vs early imatinib (trend) . | ||
| Significant infection phase I induction | 112/254 (44%) | 84/169 (50%) | 43/83 (52%) | 41/86 (48%) | P = .3 | P = .6 | P = .4 |
| Significant infection phase II induction | 130/217 (60%) | 80/144 (56%) | 41/72 (57%) | 39/72 (54%) | P = .4 | P = .7 | P = .4 |
| Died in induction (<day 56) | 13 (5%) | 9 (5%) | 3 (3%) | 6 (7%) | P = .9 | P = .5 | P = .6 |
| Survived induction, but no CR | 34/253 (13%) | 5/166 (3%) | 4/83 (5%) | 1/83 (1%) | P = .0003 | P = .4 | P = .0003 |
| CR achieved after 2 phases of protocol induction | 177 (67%) | 135 (77%) | 65 (76%) | 70 (79%) | P = .02 | P = .6 | P = .05 |
| CR achieved, but a “protocol deviation” occurred in induction** | 19 (7%) | 19 (11%) | 9 (10%) | 10 (11%) | |||
| No CR following induction, but achieved CR after induction/consolidation | 20 (8%) | 5 (3%) | 5 (6%) | 0 (0%) | |||
| CR assumed, but no date available* | 3 (1%) | 2 (1%) | 0 (0%) | 2 (2%) | |||
| Overall CR | 219 (82%) | 161 (92%) | 79 (92%) | 82 (92%) | P = .004 | P = .9 | P = .008 |
| . | Number (%) . | P value . | |||||
|---|---|---|---|---|---|---|---|
| Preimatinib cohort (N = 266) . | Imatinib cohort . | ||||||
| Any imatinib (N = 175) . | Late imatinib (N = 86) . | Early imatinib (N = 89) . | Preimatinib vs any imatinib . | Late vs early imatinib . | Pre vs late vs early imatinib (trend) . | ||
| Significant infection phase I induction | 112/254 (44%) | 84/169 (50%) | 43/83 (52%) | 41/86 (48%) | P = .3 | P = .6 | P = .4 |
| Significant infection phase II induction | 130/217 (60%) | 80/144 (56%) | 41/72 (57%) | 39/72 (54%) | P = .4 | P = .7 | P = .4 |
| Died in induction (<day 56) | 13 (5%) | 9 (5%) | 3 (3%) | 6 (7%) | P = .9 | P = .5 | P = .6 |
| Survived induction, but no CR | 34/253 (13%) | 5/166 (3%) | 4/83 (5%) | 1/83 (1%) | P = .0003 | P = .4 | P = .0003 |
| CR achieved after 2 phases of protocol induction | 177 (67%) | 135 (77%) | 65 (76%) | 70 (79%) | P = .02 | P = .6 | P = .05 |
| CR achieved, but a “protocol deviation” occurred in induction** | 19 (7%) | 19 (11%) | 9 (10%) | 10 (11%) | |||
| No CR following induction, but achieved CR after induction/consolidation | 20 (8%) | 5 (3%) | 5 (6%) | 0 (0%) | |||
| CR assumed, but no date available* | 3 (1%) | 2 (1%) | 0 (0%) | 2 (2%) | |||
| Overall CR | 219 (82%) | 161 (92%) | 79 (92%) | 82 (92%) | P = .004 | P = .9 | P = .008 |